Effect of tryptophan hydroxylase 1 deficiency on the development of hypoxia-induced pulmonary hypertension

Hypertension

Volumn 49, Issue 1, 2007, Pages 232-236

  Morecroft, Ian ^a   Dempsie, Yvonne ^a   Bader, Michael ^b   Walther, Diego J ^b   Kotnik, Katarina ^b   Loughlin, Lynn ^a   Nilsen, Margaret ^a   MacLean, Margaret R ^a  

^a UNIVERSITY OF GLASGOW   (United Kingdom)

^b MAX DELBRÜCK CENTER FOR MOLECULAR MEDICINE   (Germany)

Author keywords

Hypoxia; Pulmonary circulation; Serotonin; Transgenic animals

Indexed keywords

SEROTONIN; TRYPTOPHAN HYDROXYLASE; TRYPTOPHAN HYDROXYLASE 1; UNCLASSIFIED DRUG; SEROTONIN RECEPTOR AFFECTING AGENT; TPH1 PROTEIN, MOUSE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; ENZYME DEFICIENCY; GENE DELETION; HEART RIGHT VENTRICLE HYPERTROPHY; HEART RIGHT VENTRICLE PRESSURE; HYPOXIA; IN VIVO STUDY; LUNG BLOOD VESSEL; LUNG HEMODYNAMICS; MOUSE; NONHUMAN; PRIORITY JOURNAL; PULMONARY HYPERTENSION; TISSUE REPAIR; VASOCONSTRICTION; WILD TYPE; ANIMAL; ANOXIA; DRUG EFFECT; HEART RIGHT VENTRICLE FUNCTION; MOUSE MUTANT; PATHOPHYSIOLOGY; PRESSURE; PULMONARY ARTERY; VASCULAR RESISTANCE;

ANIMALS; ANOXIA; HYPERTENSION, PULMONARY; HYPERTROPHY, RIGHT VENTRICULAR; MICE; MICE, KNOCKOUT; PRESSURE; PULMONARY ARTERY; SEROTONIN; SEROTONIN AGENTS; TRYPTOPHAN HYDROXYLASE; VASCULAR RESISTANCE; VASOCONSTRICTION; VENTRICULAR FUNCTION, RIGHT;

EID: 33847688879     PISSN: 0194911X     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.HYP.0000252210.58849.78     Document Type: Article

References (27)

1. Cogan JD, Vnencak-Jones CL, Phillips JA, Lane KB, Wheeler LA, Robbins IM, Garrison G, Hedges LK, Loyd JE. Gross BMPR2 gene rearrangements constitute a new cause for primary pulmonary hypertension. Genet Med. 2005;7:169-174.
2. Lane KB, Machado RD, Pauciulo MW, Thomson JR, Phillips JA, Loyd JE, Nichols WC, Trembath RC. Heterozygous germline mutations in BMPR2, encoding a TGF-beta receptor, cause familial primary pulmonary hypertension. Nat Genet. 2000;26:81-84.
3. Eddahibi S, Humbert M, Fadel E, Raffestin B, Darmon M, Capron F, Simonneau G, Dartevelle P, Hamon M, Adnot S. Serotonin transporter overexpression is responsible for pulmonary artery smooth muscle hyperplasia in primary pulmonary hypertension. J Clin Invest. 2001;108:1141-1150.
4. MacLean MR, Herve P, Eddahibi S, Adnot S. 5-hydroxytryptamine and the pulmonary circulation: receptors, transporters and relevance to pulmonary arterial hypertension. Br J Pharmacol. 2000;131:161-168.
5. Herve P, Launay JM, Scrobohaci ML, Brenot F, Simonneau G, Petitpretz P, Poubeau P, Cerrina J, Duroux P, Drouet L. Increased plasma serotonin in primary pulmonary-hypertension. Am J Med. 1995;99:249-254.
6. Eddahibi S, Raffestin B, Pham I, Launay JM, Aegerter P, Sitbon M, Adnot S. Treatment with 5-HT potentiates development of pulmonary hypertension in chronically hypoxic rats. Am J Physiol Heart Circ Physiol. 1997;41:H1173-H1181.
7. Long L, MacLean MR, Jeffery TK, Morecroft I, Yang XD, Rudarakanchana N, Southwood M, James V, Trembath RC, Morrell NW. Serotonin increases susceptibility to pulmonary hypertension in BMPR2-deficient mice. Circ Res. 2006;98:818-827.
8. Eddahibi S, Hanoun N, Lanfumey L, Lesch KP, Raffestin B, Hamon M, Adnot S. Attenuated hypoxic pulmonary hypertension in mice lacking the 5-hydroxytryptamine transporter gene. J Clin Invest. 2000;105:1555-1562.
9. Guignabert C, Izikki M, Tu LI, Li ZL, Zadigue P, Barlier-Mur AM, Hanoun N, Rodman D, Hamon M, Adnot S, Eddahibi S. Transgenic mice overexpressing the 5-hydroxytryptamine transporter gene in smooth muscle develop pulmonary hypertension. Circ Res. 2006;98:1323-1330.
10. MacLean MR, Deuchar GA, Hicks MN, Morecroft I, Shen SB, Sheward J, Colston J, Loughlin L, Nilsen M, Dempsie Y, Harmar A. Overexpression of the 5-hydroxytryptamine transporter gene - effect on pulmonary hemodynamics and hypoxia-induced pulmonary hypertension. Circulation. 2004;109:2150-2155.
11. Callebert J, Esteve JM, Herve P, Peoc'h K, Tournois C, Drouet L, Launay JM, Maroteaux L. Evidence for a control of plasma serotonin levels by 5-hydroxytryptamine(2B) receptors in mice. J Pharmacol Exp Ther. 2006;317:724-731.
12. Walther DJ, Bader M. A unique central tryptophan hydroxylase isoform. Biochem Pharmacol. 2003;66:1673-1680.
13. Eddahibi S, Guignabert C, Barlier-Mur AM, Dewachter L, Fadel E, Dartevelle P, Humbert M, Simonneau G, Hanoun N, Saurini F, Hamon M, Adnot S. Cross talk between endothelial and smooth muscle cells in pulmonary hypertension - critical role for serotonin-induced smooth muscle hyperplasia. Circulation. 2006;113:1857-1864.
14. Walther DJ, Peter JU, Bashammakh S, Hortnagl H, Voits M, Fink H, Bader M. Synthesis of serotonin by a second tryptophan hydroxylase isoform. Science. 2003;299:76.
15. Keegan A, Morecroft I, Smillie D, Hicks MN, MacLean MR. Contribution of the 5-HT1B receptor to hypoxia-induced pulmonary hypertension - Converging evidence using 5-HT1B-receptor knockout mice and the 5-HT1B/1D-receptor antagonist GR127935. Circ Res. 2001;89:1231-1239.
16. Helgesen KG, Bjertnaes L. The effect of ketanserin on hypoxia-induced vasoconstriction in isolated lungs. Int J Microcirc Clin Exp. 1986;5:65-72.
17. Lawrie A, Spiekerkoetter E, Martinez EC, Ambartsumian N, Sheward WJ, MacLean MR, Harmar AJ, Schmidt AM, Lukanidin E, Rabinovitch M. Interdependent serotonin transporter and receptor pathways regulate S100A4/Mts1, a gene associated with pulmonary vascular disease. Circ Res. 2005;97:227-235.
18. Liu YL, Suzuki YJ, Day RM, Fanburg BL. Rho kinase-induced nuclear translocation of ERK1/ERK2 in smooth muscle cell mitogenesis caused by serotonin. Circ Res. 2004;95:579-586.
19. Pan J, Copland I, Post M, Yeger H, Cutz E. Mechanical stretch-induced serotonin release from pulmonary neuroendocrine cells: implications for lung development. Am J Physiol Lung Cell Mol Physiol. 2006;290:L185-L193.
20. Kay JM, Keane PM, Suyama KL. Pulmonary-hypertension induced in rats by monocrotaline and chronic hypoxia is reduced by parachlorophenylalanine. Respiration. 1985;47:48-56.
21. Tucker A, Bryant SE, Frost HH, Migally N. Chemical sympathectomy and serotonin inhibition reduce monocrotaline-induced right ventricular hypertrophy in rats. Can J Physiol Pharmacol. 1983;61:356-362.
22. Cote F, Fligny C, Fromes Y, Mallet J, Vodjdani G. Recent advances in understanding serotonin regulation of cardiovascular function. Trends Mol Med. 2004;10:232-238.
23. Cote F, Thevenot E, Fligny C, Fromes Y, Darmon M, Ripoche MA, Bayard E, Hanoun N, Saurini F, Lechat P, Dandolo L, Hamon M, Mallet J, Vodjdani G. Disruption of the nonneuronal tph1 gene demonstrates the importance of peripheral serotonin in cardiac function. Proc Natl Acad Sci USA. 2003;100:13525-13530.
24. Ni W, Wilhelm CS, Bader M, Murphy DL, Lookingland K, Watts SW. (+)-Norfenfluramine-induced arterial contraction is not dependent on endogenous 5-hydroxytryptamine or 5-hydroxytryptamine transporter. J Pharmacol Exp Ther. 2005;314:953-960.
25. Deuchar GA, Hicks MN, Cobbe SM, Docherty CC, MacLean MR. Pulmonary responses to 5-hydroxytryptamine and endothelin-1 in a rabbit model of left ventricular dysfunction. Cardiovasc Res. 1998;38:500-507.
26. MacLean MR, Morecroft I. Increased contractile response to 5-hydroxytryptamine(1)-receptor stimulation in pulmonary arteries from chronic hypoxic rats: role of pharmacological synergy. Br J Pharmacol. 2001;134:614-620.
27. Nebigil CG, Etienne N, Messaddeq N, Maroteaux L. Serotonin is a novel survival factor of cardiomyocytes: mitochondria as a target of 5-HT2Breceptor signaling. FASEB J. 2003;17:1373-1397.